nDatalyze Corp (NDATF) Fair Value & Analysis
Healthcare · US · Market cap $6.1M
nDatalyze Corp
NDATF · US
Fair value as of: Jul 29, 2026
From 1 valuation models · updated 13 days ago
Below-average quality, and screening another 70% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0320). The favourable scenario is already priced in.
- Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.
How to read this chart
60‑month range $0.0109 – $0.2590 · fair‑value band $0.0240 – $0.0320 · the $0.0800 price screens above the $0.0240 fair value. Dashed = 300-day average. As of Jul 29, 2026.
Analysis
nDatalyze Corp (NDATF) currently trades at $0.0800, while our model-based Fair Value estimate is $0.0240, implying the stock looks roughly 70.0% overvalued today. The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
It earns a return on equity of -59.8%. Fundamentals as of Jul 29, 2026
Our scenario range runs from $0.0240 (bear case) to $0.0320 (bull case); at $0.0800, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at -70%, NDATF screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when NDATF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Jul 29, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 84
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
nDatalyze Corp. provides technologically based solutions related to applying machine learning to a records database to predict probable mental health conditions. It offers Sigmund, a machine-learning-based online mental health application for the mental health system, such as misdiagnosis and mis prescription.
Full company description
nDatalyze Corp. provides technologically based solutions related to applying machine learning to a records database to predict probable mental health conditions. It offers Sigmund, a machine-learning-based online mental health application for the mental health system, such as misdiagnosis and mis prescription. The company was formerly known as MedXtractor Corp. and changed its name to nDatalyze Corp. in October 2021. nDatalyze Corp. was incorporated in 2018 and is headquartered in Calgary, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
nDatalyze Corp reported revenue of $1.7K in FY2025 versus $663K in FY2021, a compound −77.4%/yr. Reported net income was −$554K in FY2025.
NDATF screens 70% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 126 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $190.12 | $95.12 | -50% |
| Pro Medicus Limited PME | A$194.84 | A$23.74 | -88% |
| BrightSpring Health Services, Inc BTSG | $68.16 | $21.31 | -69% |
| HealthEquity, Inc HQY | $97.67 | $56.63 | -42% |
| Hinge Health, Inc HNGE | $88.80 | $24.03 | -73% |
| 10x Genomics, Inc TXG | $45.75 | $17.18 | -62% |
| Waystar Holding WAY | $22.69 | $12.86 | -43% |
| Doximity, Inc DOCS | $22.21 | $17.18 | -23% |
| Privia Health Group PRVA | $28.10 | $5.30 | -81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,846 | ₹860.28 | -53% |
Compare nDatalyze Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is nDatalyze Corp (NDATF) overvalued or undervalued?
What is the fair value of NDATF?
What is the quality score of NDATF?
What is the net profit margin of NDATF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track nDatalyze Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.